Xcout IntelSign inSubscribe
Company directory

Browse companies — page 14 of 35

Every company in Xcout Intel's live graph, 100 at a time. Click through for competitors, funding, hiring signals and more. Back to the companies hub.

Aurora Cannabis Inc.ACB · Drug Manufacturers - Specialty & GenericEdmonton, Canada
Public

Aurora Cannabis Inc. is a leading company in the global cannabis industry, focusing on the cultivation, production, and sale of various cannabis and cannabis-derived products across Canada and internationally. Beyond its core product offerings, the company engages in a broad spectrum of related activities, including the design and engineering of facilities, cannabis breeding programs, research and development, and both wholesale and retail distribution channels. For medical users, Aurora provides a diverse selection of products such as different strains of dried cannabis, cannabis oils, capsules, and topical kits. Their inventory also includes ancillary items like vaporizers, vaporizer accessories, herb mills (specifically for CanniMed products), grinders, and secure containers for vaporizers. The company is actively involved in developing advanced medical cannabis products, with ongoing work on oral, topical, edible, and inhalable formulations. Furthermore, Aurora manages CanvasRX, a network of centers dedicated to cannabis counseling and community outreach. Its service portfolio extends to providing patient support, specialized design and construction services, and comprehensive analytical testing for cannabis products. Aurora Cannabis Inc. manages an extensive collection of brands, including Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. The company's main corporate office is located in Edmonton, Canada.

Market cap$254M
Employees1,028
Aurora Cannabis Inc. competitors & alternatives →
CCC Intelligent Solutions Holdings Inc.CCC · SaaSChicago, United States
PublicAI 64/100 ▲Green 2/100 ▲

CCC Intelligent Solutions Holdings Inc. specializes in providing a comprehensive suite of digital solutions, encompassing cloud computing, mobile tools, artificial intelligence (AI), telematics, and hyperscale technologies, all designed for the property and casualty (P&C) insurance industry. At its core, the company operates a robust Software-as-a-Service (SaaS) platform. This platform is instrumental in digitizing vital, AI-driven workflows, streamlining commercial interactions, and seamlessly connecting various stakeholders across the P&C insurance ecosystem. This extensive network includes insurance carriers, collision repair facilities, parts providers, automotive manufacturers, financial institutions, and other relevant parties. CCC Intelligent Solutions offers a diverse portfolio of specialized products grouped into several key categories. These include: CCC Insurance Solutions: Covering workflow, estimating, total loss, AI & analytics, and casualty management. CCC Repair Solutions: Such as network management, repair workflow, and quality assurance. CCC Other Ecosystem Solutions: Encompassing parts, automotive manufacturer support, lender services, and payments. CCC International Solutions. Founded in 1980, the company maintains its corporate headquarters in Chicago, Illinois.

Market cap$3.8B
Employees2,185
AWSPythonAzureTerraformKubernetes
CCC Intelligent Solutions Holdings Inc. competitors & alternatives →
CG Oncology, Inc.CGON · BiopharmaceuticalsDallas, United States
Public

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.

Market cap$7B
Employees142
CG Oncology, Inc. competitors & alternatives →
ConnectOne Bancorp, Inc.CNOB · BankingEnglewood Cliffs, United States
Public

ConnectOne Bancorp, Inc. (CNOB) serves as the holding company for ConnectOne Bank, a financial institution providing a comprehensive array of commercial banking products and services. The bank caters to small and medium-sized businesses, local professionals, and individual clients across its operating regions, which include Northern New Jersey, the greater New York Metropolitan area, and the South Florida market. Its offerings include a variety of deposit accounts such as personal and business checking, retirement plans, money market accounts, and both time and savings deposits. ConnectOne Bank extends diverse credit facilities, encompassing secured and unsecured consumer and commercial business loans, revolving lines of credit, commercial mortgage loans, residential mortgages for primary and secondary residences, home equity loans, bridge loans, other personal purpose loans, and financing for commercial construction and real estate projects. Beyond lending and deposits, the company provides essential banking services such as check cards, ATM cards, credit cards, wire transfers, automated teller machine access, online banking platforms, treasury direct services, Automated Clearing House (ACH) origination, mobile banking via phone, secure safe deposit boxes, and remote deposit capture capabilities. The bank maintains an extensive physical presence, operating eight branches in Bergen County, five in Union County, and one each in Morris, Essex, Hudson, and Monmouth Counties in New Jersey. In New York, it has an office in Manhattan, one in Nassau County on Long Island, another in Astoria, and five additional branches situated throughout the Hudson Valley. Furthermore, it operates a financial center in West Palm Beach, Florida. Originally incorporated in 1982 as Center Bancorp, Inc., the company adopted its current name, ConnectOne Bancorp, Inc., in July 2014. Its corporate headquarters are located in Englewood Cliffs, New Jersey.

Market cap$1.7B
Employees489
ConnectOne Bancorp, Inc. competitors & alternatives →
Eagle Financial Services IncEFSI · BankingBerryville, United States
Public

Eagle Financial Services, Inc. functions as the parent company for Bank of Clarke County, delivering a comprehensive array of retail and commercial banking solutions across the Shenandoah Valley and Northern Virginia regions. Their core offerings include various deposit accounts, such as checking, NOW, money market, and standard savings accounts, alongside both demand and time deposits. The institution maintains a diverse loan portfolio, encompassing financing for single-to-four-family residential properties, commercial real estate ventures, construction and land development projects, and commercial and industrial enterprises. Additionally, they provide a range of consumer lending options, both secured and unsecured, including personal installment loans, lines of credit, auto loans, and credit card services. Beyond traditional banking, Eagle Financial Services offers personal and retirement planning assistance. Their investment services are extensive, featuring tax-deferred annuities, IRAs and rollovers, mutual funds, retirement and college savings plans, various insurance products (life, long-term care), fixed-income investments, brokerage CDs, and both full-service and discount brokerage options. They also facilitate non-deposit investment products and provide title insurance. To ensure convenient access, the company supports ATM and debit card services, alongside modern telephone, internet, and mobile banking platforms. For commercial clients, specialized services like ACH origination and remote deposit capture are available. The company's physical presence includes twelve full-service branches, two loan production offices, a dedicated wealth management office, and a drive-through only facility. Complementing these are 13 ATM locations, strategically placed throughout the Virginia communities of Berryville, Winchester, Boyce, Stephens City, Purcellville, Warrenton, Leesburg, Ashburn, and Fairfax. Established in 1881, Eagle Financial Services, Inc. is headquartered in Berryville, Virginia.

Market cap$247.6M
Employees225
Eagle Financial Services Inc competitors & alternatives →
Exagen Inc.XGN · BiotechnologyVista, United States
Public

Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.

Market cap$113.1M
Employees209
Exagen Inc. competitors & alternatives →
FB Financial CorporationFBK · BankingNashville, United States
Public

FB Financial Corporation functions as the parent entity for FirstBank, offering an extensive array of commercial and consumer banking solutions tailored for businesses, professionals, and individual clients. The company organizes its activities into two primary divisions: Banking and Mortgage. Its deposit offerings include checking, demand, money market, savings accounts, time deposits, and certificates of deposit. For lending, FB Financial provides a wide range of products for corporate, commercial, and consumer customers, such as financing for owner-occupied and investment commercial real estate, residential mortgages for single-family to four-family homes and multi-family units, commercial and industrial loans, construction financing, land acquisition, and land development loans. Consumer credit options feature residential lines of credit, loans for vehicles (cars, boats, and other recreational vehicles), manufactured homes (excluding land), and personal lines of credit. Additionally, the company engages in mortgage origination and delivers mortgage banking services through its branch network across the southeastern U.S. and via its digital platforms. Further services include trust, insurance, investment advisory, and modern online and mobile banking capabilities. As of December 31, 2021, FB Financial maintained a physical presence with 82 full-service and 9 limited-service bank branches across Tennessee, Northern Alabama, Southern Kentucky, and Northern Georgia, in addition to 23 mortgage offices situated throughout the southeastern United States. The company, which originated in 1906, was formerly known as First South Bancorp, Inc., before adopting the name FB Financial Corporation in 2016, and its headquarters are located in Nashville, Tennessee.

Market cap$2.6B
Employees1,594
FB Financial Corporation competitors & alternatives →
Hagerty, Inc.HGTY · InsurtechTraverse City, United States
Public

Hagerty, Inc. operates globally, serving as an insurance agency that specializes in policies for automobiles and boats, in addition to offering reinsurance products. Beyond its core insurance offerings, the company provides a suite of services and platforms: Hagerty Media distributes content through its HDC Magazine, various video productions, and a dedicated YouTube channel. HDC (Hagerty Drivers Club) is a subscription service that grants members access to the HDC Magazine, exclusive automotive events, proprietary vehicle valuation tools, emergency roadside assistance, and special vehicle-related discounts. HVT (Hagerty Valuation Tools) allows customers to access both current and historical pricing data for collector vehicles such as cars, trucks, SUVs, and motorcycles. Hagerty Events organizes a wide variety of gatherings, from intimate meetings to large-scale productions. DriveShare functions as a peer-to-peer platform for renting out classic and unique vehicles. MotorsportReg is an online system that streamlines membership, licensing, and event management for motorsports, automating aspects like event listings, registration processes, and payment collection. Hagerty Garage + Social furnishes clubhouses and secure storage facilities for vehicles. The company's primary operations are based in Traverse City, Michigan.

Market cap$4.7B
Employees1,733
Hagerty, Inc. competitors & alternatives →
Houlihan LokeyHLI · Investment BankingLos Angeles, United States
Public

Houlihan Lokey, Inc. is a prominent global investment banking firm offering a comprehensive suite of financial advisory services. These include expertise in mergers and acquisitions (M&A), capital markets, financial restructuring, and valuation. The company's operations are divided into three core segments: The Corporate Finance division provides broad financial guidance. It assists both public and private entities with strategic buy-side and sell-side transactions and a variety of capital-raising activities, such as leveraged loans, private mezzanine debt, high-yield debt, initial public offerings (IPOs), follow-on offerings, convertibles, equity private placements, and private equity investments. This segment also advises financial sponsors on diverse deal structures and liability management initiatives. The Financial Restructuring segment guides debtors, creditors, and other involved parties through complex recapitalization and deleveraging processes. Its specialized advisory services encompass the design, negotiation, and confirmation of reorganization plans, the structuring and analysis of exchange offers, corporate viability assessments, expert testimony for dispute resolution, and the procurement of debtor-in-possession (DIP) financing. The Financial and Valuation Advisory group specializes in appraising various asset types, including entire businesses, illiquid debt and equity securities, and intellectual property. It delivers critical fairness opinions for M&A and other transactions, as well as solvency opinions for corporate spin-offs and dividend recapitalizations, alongside other financial assessments. This segment further contributes to dispute resolution services. Established in 1972, Houlihan Lokey serves a diverse clientele, including corporations, institutions, and governmental entities. Headquartered in Los Angeles, California, the firm maintains a significant international presence with offices located across the United States, Europe, the Middle East, and the Asia-Pacific region.

Market cap$9.7B
Employees2,800
Houlihan Lokey competitors & alternatives →
Immunocore Holdings plcIMCR · BiotechAbingdon, United Kingdom
Public

Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.

Market cap$1.5B
Employees493
Immunocore Holdings plc competitors & alternatives →
LSB Industries, Inc.LXU · ManufacturingOklahoma City, United States
Public

LSB Industries, Inc. specializes in the production, distribution, and sale of a diverse array of chemical compounds. The company is a key supplier of nitrogen-based agricultural inputs, including ammonia, fertilizer-grade ammonium nitrate (HDAN), urea ammonia nitrate, and NPK blends, which are essential for enhancing the growth of corn and various other crops. Beyond agriculture, LSB provides a broad spectrum of industrial chemicals. These encompass high-purity and commercial-grade ammonia, high-purity ammonium nitrate, sulfuric acids, mixed nitrating acids, carbon dioxide, diesel exhaust fluids, as well as various concentrations of nitric acids. These products serve a wide array of industrial applications, such as semiconductor manufacturing, polyurethane production, pulp and paper processing, water treatment, metals and vanadium processing, power plant emission control, refrigeration, and horticulture. Furthermore, LSB is a significant producer of chemicals for the mining sector. Its offerings include industrial-grade ammonium nitrate and HDAN solutions, critical components for ammonium nitrate fuel oil (ANFO) and specialized emulsions used in surface mining, quarry operations, and construction projects. The company distributes its products through a network of distributors and directly to end-users across the United States, Mexico, and Canada, catering to the agricultural, industrial, and mining industries. Established in 1968, LSB Industries, Inc. operates from its headquarters in Oklahoma City, Oklahoma.

Market cap$734.4M
Employees513
LSB Industries, Inc. competitors & alternatives →
Lyell Immunopharma, Inc.LYEL · BiotechnologySouth San Francisco, United States
Public

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Market cap$213.4M
Employees161
Lyell Immunopharma, Inc. competitors & alternatives →
Mereo BioPharma Group plcMREO · BiotechLondon, United Kingdom
Public

Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.

Market cap$56.3M
Employees36
Mereo BioPharma Group plc competitors & alternatives →
Nektar Therapeutics0UNL · BiotechSan Francisco, United States
Public

Nektar Therapeutics is a biopharmaceutical firm dedicated to identifying and advancing medical treatments for critical health conditions lacking effective therapies, serving markets across the United States and globally. Its diverse pipeline features several promising candidates: Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma. This same compound is also being investigated in Phase 2 trials for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer, in Phase 1/2A for squamous cell carcinoma of the head and neck, in Phase 1/2 for various solid tumors, and in Phase 1B for COVID-19. Another asset, NKTR-358, a cytokine Treg stimulant, is progressing through Phase 2 clinical trials for systemic lupus erythematosus and ulcerative colitis, alongside Phase 1B studies for atopic dermatitis and psoriasis. Furthermore, NKTR-255, an IL-15 receptor agonist, is undergoing Phase 1/2 clinical trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. The company's portfolio also includes NKTR-262, a toll-like receptor agonist in Phase 1/2 trials for solid tumors, among other developmental drug candidates. Nektar has established significant collaborative agreements with a wide array of pharmaceutical companies, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Founded in 1990, Nektar Therapeutics is headquartered in San Francisco, California.

Market cap$1.4B
Employees63
Nektar Therapeutics competitors & alternatives →
Ooma, Inc.OOMA · TelecomSunnyvale, United States
Public

Ooma, Inc. delivers a diverse range of communication solutions and associated technological innovations to both commercial clients and individual users across the United States and Canada. For businesses, Ooma offers an array of solutions. These include Ooma Office, a scalable, cloud-based multi-user communication platform tailored for small to mid-sized enterprises. An enhanced version, Ooma Office Pro, expands these capabilities with features like high-definition video conferencing, call recording, advanced call blocking, and voicemail transcription. The company also provides Ooma Connect for reliable fixed wireless internet, Ooma Managed Wi-Fi as an easy-to-deploy enterprise-grade wireless network, and Ooma Enterprise, its comprehensive unified-communications-as-a-service (UCaaS) offering. On the consumer front, Ooma supplies various home communication technologies. This includes Ooma AirDial, a modern take on traditional landline service; Ooma Telo Basic, offering unlimited domestic calling within the U.S.; and Ooma Premier, a subscription-based package of enhanced calling functionalities. PureVoice HD offers dedicated residential phone services. The flagship Ooma Telo serves as a primary home communications hub, with Ooma Telo 4G extending this by integrating a 4G cellular adapter and battery backup for increased resilience. Beyond these core offerings, Ooma also develops a range of supplementary products and applications. Users can leverage the Ooma Mobile HD app for calls and feature access on the go, or opt for Ooma Telo Air, a wireless variant of the Telo unit incorporating Wi-Fi and Bluetooth. For home security, Ooma Smart Security provides a comprehensive monitoring platform, complemented by the Talkatone mobile application. The company distributes its solutions through multiple channels, including direct sales, partnerships with distributors, retailers, and resellers, in addition to its online presence. Established in 2003, Ooma, Inc. maintains its corporate headquarters in Sunnyvale, California.

Market cap$541.8M
Employees1,420
Ooma, Inc. competitors & alternatives →
Ready Capital CorporationRC · REIT - MortgageNew York City, United States
Public

Ready Capital Corporation is a U.S.-based entity primarily engaged in the real estate finance sector. Its business activities encompass the procurement, generation, administration, servicing, and funding of various loan types, including commercial loans of small to moderate value (SBC loans), those guaranteed by the Small Business Administration (SBA loans), and residential mortgages. Additionally, it deals in mortgage-backed securities, predominantly supported by SBC loans or other property-linked financial instruments. The organization conducts its operations through three distinct divisions: SBC Lending and Acquisitions: This division, leveraging its subsidiary ReadyCap Commercial, LLC, creates SBC loans. These loans are typically collateralized by investor properties, whether stable or undergoing transition, and are sourced via multiple origination avenues. Small Business Lending: Operating through ReadyCap Lending, LLC, this segment focuses on the acquisition, generation, and servicing of owner-occupied loans. These are secured by guarantees from the SBA, specifically under its Section 7(a) Program. Residential Mortgage Banking: Via its subsidiary GMFS, LLC, this division is responsible for initiating residential mortgage loans. For federal income tax considerations, the company holds the designation of a real estate investment trust (REIT). Consequently, it typically avoids federal corporate income taxation, provided it disburses a minimum of 90% of its taxable earnings to its shareholders. Historically, the firm operated as Sutherland Asset Management Corporation before adopting the name Ready Capital Corporation in September 2018. Established in 2007, its main office is situated in New York City, New York.

Market cap$268.5M
Employees442
Ready Capital Corporation competitors & alternatives →
ServisFirst Bancshares, Inc.SFBS · BankingBirmingham, United States
Public

ServisFirst Bancshares, Inc. operates as the parent entity for ServisFirst Bank, providing a comprehensive range of financial solutions to both individual consumers and corporate clients. Its deposit offerings encompass checking, savings, money market, and individual retirement accounts, in addition to certificates of deposit. The company extends diverse lending options, including commercial credit facilities for working capital, business expansion, and the acquisition of property, plant, and equipment, alongside commercial lines of credit. It also finances commercial and residential real estate, as well as construction and development ventures. For individuals, consumer loans cover home equity, vehicle purchases, and both secured and unsecured personal financing. Beyond these core services, ServisFirst Bancshares offers modern conveniences such as telephone and mobile banking, direct deposit, online banking, ATMs, debit cards, and Visa credit cards. Specialized services include treasury and cash management, wire transfers, night depository, banking-by-mail, remote capture, and correspondent banking for other financial institutions. The company also manages its subsidiary's participations in residential mortgages and commercial real estate loans originated across Alabama, Florida, Georgia, and Tennessee. Founded in 2005 and based in Birmingham, Alabama, ServisFirst Bancshares maintains 23 full-service branches throughout Alabama, Florida, Georgia, South Carolina, and Tennessee, complemented by two loan production offices located in Florida.

Market cap$4.8B
Employees636
ServisFirst Bancshares, Inc. competitors & alternatives →
Usio, Inc.USIO · FintechSan Antonio, United States
Public

Usio, Inc., established in 1998 and headquartered in San Antonio, Texas, is a company specializing in delivering comprehensive electronic payment solutions to a diverse client base of merchants and enterprises throughout the United States. The company's offerings encompass a broad spectrum of automated clearing house (ACH) processing options, in addition to services for credit, debit, and prepaid card transactions. Key ACH services include the electronic re-presentation of non-sufficient funds (NSF) consumer checks, known as "Represented Check," and the conversion of consumer paper checks into electronic payments for accounts receivable, termed "Accounts Receivable Check Conversion." Usio further provides merchant account services, facilitating the processing of card-based payments across major networks such as VISA, MasterCard, American Express, Discover, and JCB. These services are accessible through online terminals via a website or through physical terminals for retail operations. The firm has also developed a proprietary web-based platform that enables businesses to manage both one-time and recurring payments using e-checks or credit cards. Complementing this, an interactive voice response (IVR) telephone system is available, empowering companies to accept direct customer payments over the phone, also utilizing e-checks or credit cards. Usio is actively involved in the issuance of prepaid and incentive cards and operates a dedicated platform for core prepaid processing. Beyond its primary payment solutions, the company extends its services to include electronic bill presentment, document composition and decomposition, and comprehensive printing and mailing services. These additional offerings cater to various industry verticals, including utility providers and financial institutions. Its ACH products and services are primarily distributed through a network of resellers, while its prepaid card programs are marketed directly to governmental bodies, corporations, and consumers online. The company adopted its current name, Usio, Inc., in June 2019, having previously operated as Payment Data Systems, Inc.

Market cap$53.3M
Employees107
Usio, Inc. competitors & alternatives →

Company intelligence, live

Profiles, competitors, funding, the investor graph, hiring signals, tech stacks, leadership and corporate events — for every company that matters, continuously updated.

Subscribe to Xcout Intel →